TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26231519

Group type: EXPERIMENTAL
Intervention: Medium Intensity 1 (MI1) - Specialized antenatal breastfeeding education session for fathers with supporting print materials
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Medium Intensity 2 (MI2) - Antenatal and postnatal social support intervention delivered via a smartphone application
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: High Intensity (HI) - Combination of MI1 and MI2 interventions
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Usual Care Control Group (CG)
Number of subjects: 1600
Study: 23948351

Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg, three times per day)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Gefitinib (250 mg, once per day)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 400
Study: 22168530

Group type: EXPERIMENTAL
Intervention: My Asthma Portal (MAP) and usual care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 80
Study: 18950332

Group type: COMPARATOR
Intervention: GA group: general anesthesia with sevoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GA+CP group: GA with sevoflurane, combined with caudal anesthesia of plain Bupivacaine (1.25 ml x kg(‐1) of 0.2%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GA+CA group: sevoflurane GA combined with caudal anesthesia of epinephrine‐added Bupivacaine (1.25 ml x kg(‐1) of 0.2% Bupivacaine plus 1/200,000 epinephrine)
Number of subjects: 30
Study: 17163246

Group type: EXPERIMENTAL
Intervention: Fenspiride (stage 1 COPD)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fenspiride (stage 2 COPD)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fenspiride (exacerbations of COPD)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Beclomethasone (stage 2 COPD)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control groups (stages 1 and 2 COPD)
Number of subjects: 58
Study: 14707438

Group type: EXPERIMENTAL
Intervention: Brazilian version of the Recent Life Events Interview
Number of subjects: 41
Study: 9674663

Group type: EXPERIMENTAL
Intervention: Seattle Angina Questionnaire (SAQ)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Short Form Health Survey (SF-36)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Quality of Life Index-Cardiac Version III (QLI)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Canadian Cardiovascular Society Classification (CCSC)
Number of subjects: 107
Study: 7640102

Group type: EXPERIMENTAL
Intervention: iohexol 350 mg I/ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: iopamidol 370 mg I/ml
Number of subjects: 0
Study: 2769441

Group type: EXPERIMENTAL
Intervention: Acupressure wristbands for five days
Number of subjects: 16

Group type: COMPARATOR
Intervention: No therapy for five days followed by acupressure wristbands for five days
Number of subjects: 16
Study: 1071672

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study: 27171130

Group type: EXPERIMENTAL
Intervention: Mini-scleral lens with low apical clearance (100 to 200 µm)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mini-scleral lens with medium apical clearance (200 to 300 µm)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mini-scleral lens with high apical clearance (greater than 300 µm)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Smaller diameter lenses
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Central corneal thickness measured with OCT
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Central corneal thickness measured with Pentacam
Number of subjects: 11
Study: 24140326

Group type: COMPARATOR
Intervention: Capsicum (2g/cow daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Garlic (2g/cow daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: All phytonutrients (curcumin, garlic, capsicum)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Phytonutrients (all treatments)
Number of subjects: 8
Study: 20875186

Group type: EXPERIMENTAL
Intervention: Carbohydrate-milk protein solution (40 g/l carbohydrate, 25 g/l milk protein)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbohydrate solution (65 g/l carbohydrate)
Number of subjects: 8
Study: 19017760

Group type: EXPERIMENTAL
Intervention: 54 mg/d genistein for 24 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 54 mg/d genistein for 24 weeks (normoinsulinemic subgroup)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 54 mg/d genistein for 24 weeks (hyperinsulinemic subgroup)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 50
Study: 17712643

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Double pigtail stent insertion
Number of subjects: 50
Study: 15104196

Group type: EXPERIMENTAL
Intervention: Nasal triamcinolone acetonide (220 microg once daily) for 6 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: No intranasal corticosteroid treatment
Number of subjects: 32
Study: 11278161

Group type: EXPERIMENTAL
Intervention: Schizophrenics (deficit and non-deficit)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Deficit patients
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Schizophrenics
Number of subjects: 105

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 105
Study: 9848301

Group type: EXPERIMENTAL
Intervention: Triptorelin (3.75 mg IM)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (no triptorelin)
Number of subjects: 57
Study: 8006332

Group type: EXPERIMENTAL
Intervention: Tetracycline instillation (100 mg/ml, range: 1-4 ml)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Repeated needle aspiration
Number of subjects: 37
Study: 1857131

Group type: EXPERIMENTAL
Intervention: Randomization techniques (stratification and blocking) used in the Firm System
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prestudy evaluations of equivalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vigilant system maintenance programs
Number of subjects: 0
Study: 901705

Group type: EXPERIMENTAL
Intervention: Cimetidine (H2-receptor antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine + Chlorpheniramine (H1-receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study: 31410963

Group type: EXPERIMENTAL
Intervention: Experimental arm (anticancer therapies)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control arm (anticancer therapies)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Principal stratification
Number of subjects: 6
Study: 27879982

Group type: EXPERIMENTAL
Intervention: Resistance band exercises (conducted three times per week in 40-minute sessions, volunteer-led for the first 6 months followed by DVD-guided for the next 9 months)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 150
Study: 26591403

Group type: EXPERIMENTAL
Intervention: Cilostazol (Citazol®)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cilostazol (Pletaal®)
Number of subjects: 30
Study: 23927387

Group type: EXPERIMENTAL
Intervention: Levonorgestrel releasing intrauterine system (LNG-IUS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endometrial ablation (Novasure)
Number of subjects: 0
Study: 22321501

Group type: EXPERIMENTAL
Intervention: Acrysof toric IOL (T3, T4, T5)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acrysof toric IOL (T5b)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acrysof toric IOL
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Acrysof Natural IOL, 65 eyes, 45 patients)
Number of subjects: 80
Study: 19862937

Group type: EXPERIMENTAL
Intervention: A-444C polymorphism in the LTC4S gene
Number of subjects: 275

Group type: COMPARATOR
Intervention: Nonallergic controls
Number of subjects: 275
Study: 16953985

Group type: EXPERIMENTAL
Intervention: 1 mg E2V/2.5 mg MPA daily (1 + 2.5 group)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 1 mg E2V/5 mg MPA daily (1 + 5 group)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 2 mg E2V/2.5 mg MPA daily (2 + 2.5 group)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: 2 mg E2V/5 mg MPA daily (2 + 5 group)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Discontinuation of ccHRT
Number of subjects: 419
Study: 16987360

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1 g every 6 hours)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rectal paracetamol (1 g every 6 hours)
Number of subjects: 48
Study: 14528577

Group type: EXPERIMENTAL
Intervention: Kinaesthetic mobilization
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard mobilization
Number of subjects: 104
Study: 10592405

Group type: EXPERIMENTAL
Intervention: Isotrexin (combination of isotretinoin 0.05% and erythromycin 2%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.05%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7491888

Group type: EXPERIMENTAL
Intervention: OB diet (oat bran bread, 12.5 g beta-glucan/d)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: OBE diet (oat bran with beta-glucanase, 3.8 g beta-glucan/d)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: B diet (barley, 13.0 g beta-glucan/d)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: W diet (wheat flour, 1.2 g beta-glucan/d)
Number of subjects: 9
Study: 2344168

Group type: EXPERIMENTAL
Intervention: 1% mercuric oxide ophthalmic ointment, treated twice daily for 7 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 7002691

Group type: EXPERIMENTAL
Intervention: Propranolol (2 mg bolus followed by 0.1 mg/Kg/die for the next 48 hours in continuous i.v. infusion)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 31690980

Group type: EXPERIMENTAL
Intervention: Eluvia Drug-Eluting Vascular Stent System
Number of subjects: 84

Group type: COMPARATOR
Intervention: Zilver PTX Drug-Eluting Peripheral Stent
Number of subjects: 84
Study: 31395113

Group type: EXPERIMENTAL
Intervention: Presence of oral habits
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Mouth-breathing
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Biting objects
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Self-inflicting habits
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Lip sucking
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Lip-biting habits
Number of subjects: 830
Study: 28946582

Group type: EXPERIMENTAL
Intervention: Shaker exercise and conventional dysphagia therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional dysphagia therapy
Number of subjects: 32
Study: 25622199

Group type: EXPERIMENTAL
Intervention: SS plus sertraline
Number of subjects: 69

Group type: COMPARATOR
Intervention: SS plus placebo
Number of subjects: 69
Study: 23710672

Group type: EXPERIMENTAL
Intervention: Scaling and root planing, and one or more of periodontal surgery, systemically administered amoxicillin + metronidazole or local tetracycline at pockets ≥5 mm
Number of subjects: 178
Study: 21893583

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo (+MTX)
Number of subjects: 652
Study: 19401015

Group type: EXPERIMENTAL
Intervention: Open access HSG
Number of subjects: 670

Group type: COMPARATOR
Intervention: Usual management (Control)
Number of subjects: 670
Study: 17197435

Group type: EXPERIMENTAL
Intervention: XPD Gln751C/Asp312G ('D') haplotype
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ERCC1 polymorphisms
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: XRCC3 241Met variant
Number of subjects: 100
Study: 15315566

Group type: EXPERIMENTAL
Intervention: In-out catheterization
Number of subjects: 1448

Group type: COMPARATOR
Intervention: Indwelling catheterization for 24 hours
Number of subjects: 1448
Study: 11395033

Group type: EXPERIMENTAL
Intervention: Apo A-IV infusion with deuterated leucine over a 15 h time period with hourly feeding; TRL separated by ultracentrifugation; apo A-IV isolated by immunoprecipitation and/or SDS-PAGE.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Apo A-IV infusion with deuterated leucine; TRL and plasma apo A-IV residence times (RT) and transport rates (TR) measured.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Correlation analysis of TRL apo A-IV concentrations and TR; TRL apo A-IV pool size and TRL cholesterol levels.
Number of subjects: 19
Study: 9426382

Group type: EXPERIMENTAL
Intervention: CHO+ (50g carbohydrates, 200 micrograms chromium-picolinate, 20g soluble fibre, 100 mg caffeine)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CHO (50g plain carbohydrates)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All subjects (combined analysis)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Chromium intake
Number of subjects: 33
Study: 8515824

Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 12
Study: 3574137

Group type: EXPERIMENTAL
Intervention: Aspartame in solution (3 g)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aspartame in capsules (3 g)
Number of subjects: 10
Study: 30798084

Group type: EXPERIMENTAL
Intervention: Chemotherapy continuation (CT-CONT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Chemotherapy discontinuation (CT-DISC)
Number of subjects: 67
Study: 28255557

Group type: EXPERIMENTAL
Intervention: Single-task trials (walking without distraction)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Dual-task trials (walking while conversing on a cell phone)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Physical function
Number of subjects: 195
Study: 24438467

Group type: EXPERIMENTAL
Intervention: Low intensity with BFR (50% of 1-RM with BFR)
Number of subjects: 13

Group type: COMPARATOR
Intervention: High-intensity exercise (80% of 1-RM)
Number of subjects: 13
Study: 23485955

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (50-300 mg/day)
Number of subjects: 1752

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1752
Study: 21256179

Group type: EXPERIMENTAL
Intervention: Acetyl-l-Carnitine (3g/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Acetyl-l-Carnitine (1g/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 19551353

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine ophthalmic emulsion 0.05%
Number of subjects: 37

Group type: COMPARATOR
Intervention: Artificial tear solution
Number of subjects: 37
Study: 16687452

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 15295720

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily for one month
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12795493

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional antipsychotic medications
Number of subjects: 108
Study: 9665097

Group type: EXPERIMENTAL
Intervention: Strong black tea (1600 mL/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fried onions (129 g/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fried onions (129 g/d) repeated treatment
Number of subjects: 15
Study: 7793048

Group type: EXPERIMENTAL
Intervention: X-ray computer-aided tomography (CAT) with filling of the stomach with liquid
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: X-ray computer-aided tomography (CAT) with pneumoscanning of the stomach
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Tubal scanning of the stomach
Number of subjects: 134

Group type: COMPARATOR
Intervention: Axial CAT of individual portions of the stomach
Number of subjects: 134
Study: 2572494

Group type: EXPERIMENTAL
Intervention: 0.5 mg etizolam
Number of subjects: 45

Group type: COMPARATOR
Intervention: 0.5 mg alprazolam
Number of subjects: 45

Group type: COMPARATOR
Intervention: 3 mg bromazepam
Number of subjects: 45
Study: 1098449

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31621189

Group type: EXPERIMENTAL
Intervention: VYC-12 injectable gel
Number of subjects: 131
Study: 30197226

Group type: EXPERIMENTAL
Intervention: Tongue function and bite force
Number of subjects: 245
Study: 29104904

Group type: EXPERIMENTAL
Intervention: Decentralised care plus structured support visits by trained community health workers (intervention group) for 18 months.
Number of subjects: 334

Group type: COMPARATOR
Intervention: Decentralised primary health-care clinic-based HIV care (control group) for 18 months.
Number of subjects: 334
Study: 25724569

Group type: EXPERIMENTAL
Intervention: Bdiet (high-energy breakfast, 2,946 kJ; lunch, 2,523 kJ; dinner, 858 kJ)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Bdiet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ddiet (high-energy dinner, 2,946 kJ; lunch, 2,523 kJ; breakfast, 858 kJ)
Number of subjects: 18
Study: 23820423

Group type: EXPERIMENTAL
Intervention: Unilateral laparoscopic ovarian drilling (ULOD) with thermal doses adjusted to the volume of the right ovary (60 J/cm³)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bilateral laparoscopic ovarian drilling (BLOD) with fixed doses of 600 J per ovary
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Unilateral laparoscopic ovarian drilling (ULOD)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bilateral laparoscopic ovarian drilling (BLOD)
Number of subjects: 96
Study: 21685487

Group type: EXPERIMENTAL
Intervention: etomidate
Number of subjects: 100

Group type: COMPARATOR
Intervention: propofol
Number of subjects: 100
Study: 19960974

Group type: EXPERIMENTAL
Intervention: Bailing Capsule (BC) and benazepril
Number of subjects: 60

Group type: COMPARATOR
Intervention: Benazepril alone (Control)
Number of subjects: 60
Study: 16520478

Group type: EXPERIMENTAL
Intervention: Herbal medicine interventions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Context-specific elaborations of CONSORT checklist items
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Item 4 concerning herbal medicine intervention
Number of subjects: 16
Study: 15574604

Group type: EXPERIMENTAL
Intervention: 4% amethocaine gel (1 g applied for 30 minutes before vaccination)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (1 g applied for 30 minutes before vaccination)
Number of subjects: 120
Study: 10809936

Group type: EXPERIMENTAL
Intervention: High-dose rivastigmine (6-12 mg/day)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Low-dose rivastigmine (1-4 mg/day)
Number of subjects: 699
Study: 8975854

Group type: EXPERIMENTAL
Intervention: Cold temperature (8-10 degrees C)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Tepid temperature (32 degrees C)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Warm temperature (37 degrees C)
Number of subjects: 116
Study: 1472143

Group type: EXPERIMENTAL
Intervention: loratadine 10 mg once daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: terfenadine 120 mg once daily
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: nasal peak flow
Number of subjects: 105
Study: 6708399

Group type: EXPERIMENTAL
Intervention: 0.2 mg fenoterol powder
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31562911

Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3 taken just before operation and twice daily up to 15 total doses
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3
Number of subjects: 135
Study: 28779655

Group type: EXPERIMENTAL
Intervention: 800 IU/d vitamin D
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 1000 IU/d vitamin D
Number of subjects: 121

Group type: COMPARATOR
Intervention: 400 IU/d vitamin D
Number of subjects: 121
Study: 25323601

Group type: EXPERIMENTAL
Intervention: Vertebral fractures
Number of subjects: 3673

Group type: EXPERIMENTAL
Intervention: Bone density (measured in Hounsfield Units)
Number of subjects: 3673
Study: 23229869

Group type: EXPERIMENTAL
Intervention: 5 mg low-dose intrathecal bupivacaine
Number of subjects: 49

Group type: COMPARATOR
Intervention: 10 mg standard-dose intrathecal bupivacaine
Number of subjects: 49
Study: 21744954

Group type: EXPERIMENTAL
Intervention: Novel labels mapping to actions and objects in English learners at 18 months
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Novel labels mapping to actions and objects in English learners at 14 months
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Novel labels mapping to actions in Mandarin learners at 14 months
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Novel labels mapping to actions in Mandarin learners at 18 months
Number of subjects: 128
Study: 19084838

Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure (LEEP)
Number of subjects: 70
Study: 16707915

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 15101864

Group type: EXPERIMENTAL
Intervention: Blood-containing prime (Group B, n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Crystalloid prime (Group C, n = 18)
Number of subjects: 36
Study: 10672630

Group type: EXPERIMENTAL
Intervention: Caffeine (equal to baseline daily caffeine consumption)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (during caffeine-free diet)
Number of subjects: 10
Study: 9327317

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg orally before surgery and once daily postoperatively
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1304204

Group type: EXPERIMENTAL
Intervention: Continuous curvilinear capsulorhexis (CCC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Can opener
Number of subjects: 40

Group type: COMPARATOR
Intervention: Linear capsulotomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Capsulopuncture ('postage stamp')
Number of subjects: 40
Study: 4003987

Group type: EXPERIMENTAL
Intervention: Intramuscular recombinant interferon alpha‐2 at dosages of 10 to 50 MU/d
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant interferon alpha‐2 at dosages of 10 to 50 MU/d
Number of subjects: 33